Belite Bio, Inc
NASDAQ:BLTEBiotechnology
+$0.46 today
- Market cap
- $6.29B
- Beta
- -1.24
- P/E (TTM)
- -65.9
- EPS (TTM)
- -$2.26
Volume 0.09M
Average 0.17M
BLTE Total Non-current Assets
All assets not expected to be converted to cash within one year.
Belite Bio, IncNASDAQ: BLTE
Total Non-current Assets · Q2 FY2026 · quarter ended Jun 2026
Total non-current assets rises 5233.5% from a year ago
Total non-current assets stood at $289.98M at the end of Q2 FY2026, up 5233.5% from a year earlier and up 0.2% from the prior quarter. Over 3 fiscal years it compounded at +480.2% a year.
Context
- Total non-current assets amounted to 36.6% of total assets at the end of Q2 FY2026, up 33.2 pp from a year earlier.
- Total non-current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +5233.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 286.28M USD
- Year-over-year change
- +5558.9%
- 4-year CAGR
- +320.3%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 286.28M | +5558.9% |
| FY2024 | 2024-12-31 | 5.06M | +7.6% |
| FY2023 | 2023-12-31 | 4.7M | +220.7% |
| FY2022 | 2022-12-31 | 1.47M | +59.9% |
| FY2021 | 2021-12-31 | 917K | — |
Total Non-current Assets vs competitors
How BLTE compares with its peers on the latest reported figures
- BLTE's Jun 2026 total non-current assets of $289.98M is the highest of the 6 companies compared; the peer median is $18.35M.
- Its year-over-year change of +5233.5% is the highest of 6, against a peer median of -10.5%.
- Total non-current assets amounts to 36.6% of total assets for BLTE, versus a peer median of 13.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
BLTEBelite Bio, Inc | Jun 2026 | $289.98M | +5233.5% | +480.2% | 36.6% |
| Sep 2026 | $116.53M | -18.1% | -8.9% | 55.6% | |
| Mar 2026 | $38.71M | +8.8% | +67.3% | 13.4% | |
| Mar 2026 | $18.35M | -10.5% | +23.7% | 32.3% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $11.73M | +1188.9% | — | 10.7% |
IRDOpus Genetics, Inc. | Mar 2026 | $186K | -22.2% | +221.3% | 0.3% |
| Peer median (excluding BLTE) | $18.35M | -10.5% | +45.5% | 13.4% | |
Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 17.34M | 42.09M | 88.16M | 31.68M | 352.93M |
| Short-term Investments | 0 | 0 | 0 | 113.47M | 139.49M |
| Net Receivables | 23K | 19K | 867K | 594K | 718K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 5K |
| Total Current Assets | 17.43M | 42.81M | 89.94M | 147.07M | 494.27M |
| Property, Plant & Equipment (Net) | 94K | 1.35M | 1.3M | 965K | 777K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 31K | 3.3M | 3.99M | 4.92M |
| Long-term Investments | 0 | 0 | 0 | 0 | 280.17M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 823K | 88K | 104K | 103K | 425K |
| Total Non-current Assets | 917K | 1.47M | 4.7M | 5.06M | 286.28M |
| Total Assets | 18.35M | 44.27M | 94.64M | 152.13M | 780.56M |
| Account Payables | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 24K | 456K | 876K | 992K | 2.21M |
| Total Current Liabilities | 1.64M | 2.1M | 3.63M | 6.05M | 9.88M |
| Long-term Debt | 31.81M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 31.81M | 668K | 578K | 261K | 188K |
| Total Liabilities | 33.44M | 2.77M | 4.21M | 6.31M | 10.07M |
| Common Stock | 1K | 3K | 3K | 3K | 4K |
| Retained Earnings | (27.22M) | (39.87M) | (71.5M) | (107.65M) | (185.26M) |
| Accumulated OCI | (196K) | (392K) | (374K) | (660K) | (536K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (15.09M) | 41.5M | 90.43M | 145.82M | 770.49M |
| Total Debt | 31.81M | 866K | 886K | 537K | 429K |
| Net Debt | 14.46M | (41.22M) | (87.27M) | (31.14M) | (352.5M) |
Belite Bio, Inc
NASDAQ:BLTE
Intrinsic Alpha fair value
Locked
Current Price
$156.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.